AxoGen (NASDAQ:AXGN) Price Target Raised to $56.00

AxoGen (NASDAQ:AXGN) had its price objective increased by HC Wainwright from $53.00 to $56.00 in a research note published on Thursday morning, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the medical equipment provider’s stock.

AXGN has been the topic of several other research reports. Raymond James Financial reissued an “outperform” rating and set a $57.00 target price on shares of AxoGen in a research report on Thursday. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a research note on Thursday, July 30th. Truist Financial lowered their price objective on shares of AxoGen from $60.00 to $53.00 and set a “buy” rating on the stock in a research report on Thursday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of AxoGen in a research note on Wednesday, August 26th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $60.00 target price on shares of AxoGen in a research report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, AxoGen has an average rating of “Moderate Buy” and an average target price of $57.92.

AxoGen Stock Down 0.5%

AXGN opened at $49.37 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.02 and a quick ratio of 5.04. The company’s 50-day moving average is $42.86 and its 200 day moving average is $39.45. AxoGen has a fifty-two week low of $21.68 and a fifty-two week high of $52.91. The firm has a market capitalization of $2.95 billion, a P/E ratio of -75.95 and a beta of 1.17.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $73.45 million. Research analysts expect that AxoGen will post -0.44 earnings per share for the current fiscal year.

Insider Transactions at AxoGen

In other news, EVP Marc Began sold 67,500 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the transaction, the executive vice president owned 50,135 shares of the company’s stock, valued at $2,373,390.90. This represents a 57.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Wendell sold 13,353 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the transaction, the director owned 107,976 shares of the company’s stock, valued at $5,228,197.92. The trade was a 11.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 98,503 shares of company stock valued at $4,656,947. Corporate insiders own 2.44% of the company’s stock.

Hedge Funds Weigh In On AxoGen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXGN. Nykredit A S purchased a new stake in shares of AxoGen during the second quarter worth $30,000. KBC Group NV bought a new position in shares of AxoGen in the first quarter worth $41,000. Sterling Capital Management LLC grew its position in shares of AxoGen by 858.9% in the third quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 1,589 shares in the last quarter. State of Alaska Department of Revenue grew its position in shares of AxoGen by 16.9% in the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock valued at $118,000 after purchasing an additional 409 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AxoGen during the 2nd quarter valued at $203,000. Institutional investors own 80.29% of the company’s stock.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
• Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
• Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
• Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

About AxoGen

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.